Exciting news for Capricor’s CAP1002 therapy for the treatment of cardiomyopathy in advance stage Duchenne muscular dystrophy:
- On May 13, 2020, Capricor announced positive top-line results from their HOPE-2 study with their lead candidate CAP-1002 treating Duchenne patients with an advanced stage of the disease.
- CAP1002 is a cardiac-derived cell therapy currently under investigation for the treatment of Duchenne muscular dystrophy. This biologic demonstrated improvements in upper limb, cardiac and respiratory function with no safety signals.
- Capricor is working with the FDA in the USA on making this drug available and was granted orphan drug and a rare pediatric disease designation by the FDA for the treatment of Duchenne. This means they may be eligible for a priority review.
It is not clear Capricor’s intentions for application to Health Canada, but Defeat Duchenne Canada will be following to find out more.
Click here to read the full article “Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002.”
Click here to read the full article “Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update.”
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways.
Capricor’s lead candidate, CAP-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy (DMD).
CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials.
Capricor has also established itself as one of the leading companies investigating the field of exosome science. Exosomes are nanosized particles with biologically-active contents that are secreted by cells and serve to direct or re-direct the activities of other cells and are emerging as an exciting class of potential therapeutic agents. Our studies have been showing that our exosome technology is significantly active in several disease models. Capricor plans to explore the development of exosome technology as a next-generation platform in a variety of inflammatory disorders.